AbTis, in Spotlight with ADC Technology, Aims to Target Space

AbTis, a subsidiary of Dong-A ST, has been awarded with the Korean “ARPA-H Project.” A researcher with AbTis is engaged in research. (Photo: Dong-A ST)

AbTis, a core subsidiary of Dong-A ST, is setting its sights on space.

Industry sources said AbTis, a subsidiary of Dong ST, specializing in antibody drug conjugate (ADC), has been awarded with the Korean “ARPA-H Project.” The company is exploring new opportunities.

The Korea ARPA-H Project aims to solve national difficult health care issues by implementing R&D focusing on tasks with high-cost, high-difficulty, and greater spill-over effects.

The project calls for developing new medicines for use in space.

Among the six participants are Space LinTech, KIST, Inha University Hospital, Voyager Space & NASA and Harvard University.

AbTis will be in charge of the production of new ADC drug candidates using antibodies made in the space environment, optimized process and evaluation.

The company virtually will play a leading role in new drug development using space.

Development of new drugs using the space environment has already begun.

The gravity of space is one millionth that of the earth. Uniformed and quality-high protein crystal is believed to be formed without the hindrance of gravity at the stage of protein crystallization, one of the essential stages of new drug development.

Global pharmaceutical companies have been scrambling to be engaged in new drug research using the conditions of the space environment.

AbTis is the first Korean company to be engaged in new drug development in zero gravity.

AbTis is in the spotlight in the ADC sector. The company has owned AbClick, an ADC technology that can site-selectively conjugate drugs without antibody modification.

Dozens of bio companies have been engaged in new drug development in cooperation with AbTis. AbTis itself is predicated to embark on clinical tests of new drug candidates the company has development this year.

A view of two versions of “Garglin Fresh Breath Toothpaste,” launched by Dong-A Pharmaceutical. (Photo: Dong-A Pharmaceutical)

Dong-A Pharmaceutical Releases Two Kinds of ‘Garglin Fresh Breath Toothpaste’

Dong-A Pharmaceutical has launched two versions of “Garglin Fresh Breath Toothpaste,” the company said on March 5.

Garglin Fresh Breath Toothpaste is designed to remove factors of bad mouth smells — hydrogen sulfide that causes a smell of rotten egg and methyl mercaptan that cause a smell of rotten onion.

Clinical testing showed that using Garglin Fresh Breath Toothpaste is efficacious for removing hydrogen sulfide and methyl mercaptan by more than 90 percent.

The reduction rate of the two substances remains at 80 to 90 percent even 12 hours after the toothpaste is used.

On the removal of bad odor, the latest toothpaste contains fluorine that prevents periodontal diseases as well as dental type silica, tocopherol acetate and sodium pyrophosphate that prevent gum diseases.

Garglin Fresh Breath Toothpaste also contains mint oil, green tea and xylitol that refresh the inside of the month and absence of seven harmful substances, such as benzophenone can be used by all family members.

Garglin Fresh Breath Toothpaste has two versions — spearmint and lime mint.

You can buy the latest toothpaste from Naver Brand Store and they will be sold at Coopang and Dong-A Pharmaceutical’s official mall “D Mall.”

A Dong-A Pharmaceutical official said, “The new product is developed for consumers who suffer from bad mouth smells and oral diseases, and you will feel refreshed for 12 hours after using Garglin Fresh Breath Toothpaste, reducing bad breath.”